We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STZ:NYSEConstellation Brands, Inc. Analysis

Data as of 2026-05-26 - not real-time

$145.83

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Constellation Brands is trading at $145.83, comfortably below its 20‑day (≈148.18) and 200‑day (≈147.94) simple moving averages, while the 14‑day RSI sits at 43.9, indicating a neutral but slightly bearish momentum. The MACD histogram is positive (0.48) and the signal line is deemed bullish, suggesting a modest technical upside despite the price lagging short‑term averages. Volatility remains elevated at roughly 31% over the past month, yet the stock’s beta of 0.23 points to limited systematic risk and a defensive profile within the Consumer Defensive sector.
Fundamentally, STZ posted a 11% revenue contraction year‑over‑year, but it retains solid profitability with a gross margin above 51% and an operating margin near 27%. Forward earnings estimates imply a P/E of 11.7, well below the trailing 15.2, while the dividend yield of 2.76% and a payout ratio under 45% signal sustainable income. The DCF‑derived fair value of roughly $90 marks the stock as materially overvalued at current levels, and a hefty debt‑to‑equity ratio (>130%) adds balance‑sheet pressure. Recent catalysts include a board addition from McDonald’s, a full‑redemption notice on senior debt, and the nationwide launch of a high‑ABV Modelo Chelada, all of which could help offset the recent 7.9% post‑earnings price decline and support medium‑term upside toward analyst targets near $180.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below short‑term moving averages
  • Recent earnings miss and 7.9% share decline
  • Stable dividend cushioning downside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings growth and lower forward P/E
  • Product innovation (Modelo Chelada Suprema) and board expertise
  • Analyst target median around $184 suggesting upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong brand portfolio and cash‑flow generation
  • High leverage and revenue contraction
  • Sustainable dividend yielding ~2.8%

Key Metrics & Analysis

Financial Health

Revenue Growth-11.30%
Profit Margin18.46%
P/E Ratio15.2
ROE22.64%
ROA8.51%
Debt/Equity133.57
P/B Ratio3.1
Op. Cash Flow$2.7B
Free Cash Flow$2.0B

Technical Analysis

TrendNeutral
RSI43.9
Support$139.10
Resistance$157.73
MA 20$148.18
MA 50$152.68
MA 200$147.94
MACDBullish
VolumeStable
Fear & Greed Index91.32

Valuation

Fair Value$90.26
Target Price$177.55
Upside/Downside21.75%
GradeOvervalued
TypeBlend
Dividend Yield2.76%

Risk Assessment

Beta0.23
Volatility30.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.